AU681348B2 - Asymmetrically substituted xanthine with adenosine-antagonistic properties - Google Patents

Asymmetrically substituted xanthine with adenosine-antagonistic properties Download PDF

Info

Publication number
AU681348B2
AU681348B2 AU47071/93A AU4707193A AU681348B2 AU 681348 B2 AU681348 B2 AU 681348B2 AU 47071/93 A AU47071/93 A AU 47071/93A AU 4707193 A AU4707193 A AU 4707193A AU 681348 B2 AU681348 B2 AU 681348B2
Authority
AU
Australia
Prior art keywords
der
cyclopentyl
theory
insgesamt
document
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU47071/93A
Other languages
English (en)
Other versions
AU4707193A (en
Inventor
Helmut Ensinger
Ulrike Kufner-Muhl
Franz Josef Kuhn
Erich Lehr
Joachim Mierau
Enzio Muller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of AU4707193A publication Critical patent/AU4707193A/en
Application granted granted Critical
Publication of AU681348B2 publication Critical patent/AU681348B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Laser Surgery Devices (AREA)
  • Radiation-Therapy Devices (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
AU47071/93A 1992-08-10 1993-08-05 Asymmetrically substituted xanthine with adenosine-antagonistic properties Ceased AU681348B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE4226371 1992-08-10
DE4226371 1992-08-10
DE4238423 1992-11-13
DE4238423 1992-11-13
PCT/EP1993/002077 WO1994003456A1 (de) 1992-08-10 1993-08-05 Unsymmetrisch substituierte xanthine mit adenosinantagonistischen eigenschaften

Publications (2)

Publication Number Publication Date
AU4707193A AU4707193A (en) 1994-03-03
AU681348B2 true AU681348B2 (en) 1997-08-28

Family

ID=25917371

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47071/93A Ceased AU681348B2 (en) 1992-08-10 1993-08-05 Asymmetrically substituted xanthine with adenosine-antagonistic properties

Country Status (21)

Country Link
US (1) US5719279A (OSRAM)
EP (1) EP0654033A1 (OSRAM)
JP (1) JPH08500344A (OSRAM)
KR (1) KR950702988A (OSRAM)
CN (1) CN1043348C (OSRAM)
AU (1) AU681348B2 (OSRAM)
BG (1) BG62618B1 (OSRAM)
CA (1) CA2140883A1 (OSRAM)
CZ (1) CZ286459B6 (OSRAM)
FI (1) FI950542L (OSRAM)
HU (1) HUT65734A (OSRAM)
IL (1) IL106624A (OSRAM)
MX (1) MX9304819A (OSRAM)
NZ (1) NZ254804A (OSRAM)
PL (1) PL176389B1 (OSRAM)
RU (1) RU2138500C1 (OSRAM)
SG (1) SG55038A1 (OSRAM)
SK (1) SK18595A3 (OSRAM)
TW (1) TW252044B (OSRAM)
UA (1) UA46697C2 (OSRAM)
WO (1) WO1994003456A1 (OSRAM)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW252044B (OSRAM) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5877179A (en) * 1992-09-29 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
WO1994025462A1 (en) * 1993-05-03 1994-11-10 The United States Of America, Represented By The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
DE4316576A1 (de) * 1993-05-18 1994-11-24 Boehringer Ingelheim Kg Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
GB9415529D0 (en) 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
AU4527996A (en) 1994-12-13 1996-07-03 Euro-Celtique S.A. Trisubstituted thioxanthines
EP0814809B1 (en) * 1994-12-13 2003-08-13 Euroceltique S.A. Aryl thioxanthines
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
US5786360A (en) * 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
WO1999031101A1 (en) * 1997-12-17 1999-06-24 University Of South Florida Adenosine receptor antagonists with improved bioactivity
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2336967C (en) 1998-07-10 2010-06-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
DE60041710D1 (de) 1999-11-12 2009-04-16 Biogen Idec Inc Polycycloalkylpurine als adenosinrezeptorantagonisten
PL198156B1 (pl) 1999-11-12 2008-05-30 Biogen Idec Ma Ksantyny podstawione w pozycji 8, sposób ich wytwarzania i ich zastosowanie oraz kompozycja farmaceutyczna
DE60018216T2 (de) * 1999-12-24 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Kondensierte purinderivate
CA2397366C (en) 2000-01-14 2011-03-15 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methanocarba cycloalkyl nucleoside analogues
GB0008694D0 (en) * 2000-04-07 2000-05-31 Novartis Ag Organic compounds
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
PT1757606E (pt) * 2001-02-24 2009-05-26 Boehringer Ingelheim Pharma Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
AU2003231805A1 (en) 2002-06-17 2004-02-09 Glaxo Group Limited Purine derivatives as liver x receptor agonists
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
EP1601649A4 (en) * 2003-02-19 2009-03-04 Endacea Inc A1-adenosine receptor antagonistic
AR044069A1 (es) 2003-04-25 2005-08-24 Nova Cardia Inc Un metodo de diuresis mejorada en individuos con funcion renal deteriorada
RU2318825C2 (ru) * 2003-05-06 2008-03-10 Си Ви Терапьютикс, Инк. Производные ксантина в качестве антагонистов a2b аденозинового рецептора
CA2528385C (en) * 2003-06-06 2011-03-15 Endacea, Inc. A1 adenosine receptor antogonists
JP2007506804A (ja) * 2003-06-09 2007-03-22 エンダセア， インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1891070A1 (en) * 2005-06-16 2008-02-27 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NZ619413A (en) 2006-05-04 2015-08-28 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
CA2660197A1 (en) * 2006-08-08 2008-02-14 Boehringer Ingelheim International Gmbh Pyrrolo[3,2-d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
RU2344137C1 (ru) * 2007-07-18 2009-01-20 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) Производные 8-амино-7-(2-гидроксипропил-1)-1,3-диметилксантина гидрохлорида, проявляющие гемореологическую активность
US20110112069A1 (en) * 2007-08-17 2011-05-12 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
US9522916B2 (en) 2007-12-21 2016-12-20 Constance Neely Wilson A1 adenosine receptor antagonists
US7928259B2 (en) * 2008-02-12 2011-04-19 Frx Polymers, Inc. Diaryl alkylphosphonates and methods for preparing same
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR101791403B1 (ko) * 2008-08-15 2017-10-30 베링거 인겔하임 인터내셔날 게엠베하 Ｆａｂ-관련 질환의 치료에 사용하기 위한 퓨린 유도체
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
JP5334511B2 (ja) * 2008-09-22 2013-11-06 日本精化株式会社 化粧料
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
MX2011010079A (es) 2009-03-26 2011-10-10 Mapi Pharma Ltd Proceso para la preparacion de alogliptina.
MX364651B (es) 2009-11-27 2019-05-03 Boehringer Ingelheim Int Gmbh Star Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente.
WO2011068978A1 (en) 2009-12-02 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives and dendrimer conjugates thereof
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
KR20190050871A (ko) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
DK3517539T3 (en) 2011-07-15 2023-01-16 Boehringer Ingelheim Int Farmaceutiske sammensætninger til behandling af type i og type ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
RU2643336C1 (ru) * 2016-10-03 2018-01-31 Общество с Ограниченной Ответственностью "Компания "ЭЛТА" СРЕДСТВО, ПРОЯВЛЯЮЩЕЕ АНТИТРОМБОТИЧЕСКИЙ ЭФФЕКТ ПОСРЕДСТВОМ БЛОКИРОВАНИЯ РЕЦЕПТОРОВ ТРОМБОЦИТОВ ГП IIb-IIIa (ВАРИАНТЫ)
CN109796453A (zh) * 2019-02-12 2019-05-24 南京纽邦生物科技有限公司 一种1,7-二甲基黄嘌呤的制备方法
EP4229059A1 (en) 2020-10-15 2023-08-23 Rheinische Friedrich-Wilhelms-Universität Bonn 3-substituted xanthine derivatives as mrgprx4 receptor modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0415456A2 (en) * 1989-09-01 1991-03-06 Kyowa Hakko Kogyo Co., Ltd. Xanthine compounds
WO1992000297A1 (de) * 1990-06-22 1992-01-09 Boehringer Ingelheim Kg Neue xanthinderivate
EP0501379A2 (en) * 1991-02-25 1992-09-02 Kyowa Hakko Kogyo Co., Ltd. Xanthine compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
FR2531085A1 (fr) * 1982-07-28 1984-02-03 Adir Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
CS238038B1 (en) * 1983-10-07 1985-11-13 Antonin Holy Medical drug with antivirus effect
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
US4772607A (en) * 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US4783530A (en) * 1986-11-13 1988-11-08 Marion Laboratories, Inc. 8-arylxanthines
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US5032593A (en) * 1988-07-01 1991-07-16 Marion Merrell Dow Inc. Method of treating bronchoconstriction with 1,3-unsymmetrical straight chain alkyl-substituted 8-phenylxanthines
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
ATE176470T1 (de) * 1990-10-18 1999-02-15 Kyowa Hakko Kogyo Kk Xanthinderivate
TW252044B (OSRAM) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5366977A (en) * 1992-09-29 1994-11-22 The United States Of America, As Represented By The Department Of Health And Human Services Method of treating cystic fibrosis using 8-cyclopentyl-1,3-dipropylxanthine or xanthine amino congeners

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0415456A2 (en) * 1989-09-01 1991-03-06 Kyowa Hakko Kogyo Co., Ltd. Xanthine compounds
WO1992000297A1 (de) * 1990-06-22 1992-01-09 Boehringer Ingelheim Kg Neue xanthinderivate
EP0501379A2 (en) * 1991-02-25 1992-09-02 Kyowa Hakko Kogyo Co., Ltd. Xanthine compounds

Also Published As

Publication number Publication date
JPH08500344A (ja) 1996-01-16
TW252044B (OSRAM) 1995-07-21
IL106624A0 (en) 1993-12-08
FI950542A0 (fi) 1995-02-08
IL106624A (en) 1999-01-26
HUT65734A (en) 1994-07-28
WO1994003456A1 (de) 1994-02-17
EP0654033A1 (de) 1995-05-24
SG55038A1 (en) 1998-12-21
PL307397A1 (en) 1995-05-15
CA2140883A1 (en) 1994-02-17
RU95109100A (ru) 1996-12-27
UA46697C2 (uk) 2002-06-17
CN1043348C (zh) 1999-05-12
US5719279A (en) 1998-02-17
MX9304819A (es) 1994-02-28
CZ286459B6 (en) 2000-04-12
RU2138500C1 (ru) 1999-09-27
FI950542A7 (fi) 1995-02-08
KR950702988A (ko) 1995-08-23
HU9302302D0 (en) 1993-10-28
AU4707193A (en) 1994-03-03
CN1086818A (zh) 1994-05-18
PL176389B1 (pl) 1999-05-31
CZ34895A3 (en) 1995-10-18
NZ254804A (en) 1997-01-29
SK18595A3 (en) 1995-07-11
BG62618B1 (bg) 2000-03-31
FI950542L (fi) 1995-02-08
BG99489A (bg) 1996-01-31

Similar Documents

Publication Publication Date Title
AU681348B2 (en) Asymmetrically substituted xanthine with adenosine-antagonistic properties
EP0203721B1 (en) 8-phenyl xanthines
US7034016B2 (en) 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives
US5734051A (en) 8-substituted xanthine derivatives and method of use thereof
US4089959A (en) Long-acting xanthine bronchodilators and antiallergy agents
EP0010531B1 (en) 3-alkylxanthines, processes for their preparation and compositions for use in the treatment of chronic obstructive airway disease and cardiac disease
US4120947A (en) Xanthine compounds and method of treating bronchospastic and allergic diseases
US20030171384A1 (en) 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
US4925847A (en) 6-thioxanthines
US6187780B1 (en) Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
DD211555A5 (de) Verfahren zur herstellung neuer 4-amino-6,7-dimethoxychinolin-derivate
Sakai et al. Effects of alkyl substitutions of xanthine skeleton on bronchodilation
GB2214181A (en) 1,2-ethylene diamine compounds
Daly et al. Imidazodiazepinediones: a new class of adenosine receptor antagonists
EP0531349A1 (en) 1-7 substituted xanthine derivatives having antiasthmatic activity, their salts physiologically acceptable, pharmaceutical composition containing them and process for their preparation
EP0038784A2 (en) 3,8-Dialkylxanthines, processes for their preparation and compositions containing them
EP1084123A1 (de) Neue unsymmetrisch substituierte xanthin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel mit adenosinantagonistischer wirkung
DE4325254A1 (de) Unsymmetrisch substituierte Xanthine
DE2300018C2 (de) 1-[N-Methyl-N-(β-phenyläthyl)-3-aminopropyl]- benzimidazol-Abkömmlinge
US20040038996A1 (en) 8-Quinolinxanthine and 8-isoquinolinxant hine derivatives as PDE 5 inhibitors
AU604767B2 (en) 1-hydroxyalkylxanthines, processes for their preparation and medicaments containing them
DE4207234A1 (de) Neue aminocarbonsaeure-derivate mit antiallergischer/antiasthmatischer wirkung und verfahren zu deren herstellung
JPH08134044A (ja) 新規ピリミジン化合物、中間体及びそれらの製造法
HU176344B (en) Process for producing amino-ethanol-derivatives
US4639453A (en) Substituted 1-(4-amino-6,7-dialkoxyquinazolinyl)-4 cyclohexenyl derivatives of piperazine and homopiperazine, processes for their preparation and their use, formulations containing these compounds and intermediates

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired